Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden.
Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible.
Decades of clinical immunoproteomics research resulted in the development of IMMray™, our core technology platform based on antibody microarray analysis.
IMMray™ is dedicated to the early diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The platform technology can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray™ PS (Proteome Survey). Immunovia’s technology is designed not only for cancer but also for autoimmune diseases. It is superior to conventional proteomic technologies that suffer from low throughput and impaired resolution and sensitivity.
The first test based on Immunovia’s platform, IMMray™ PanCan-d, is now under commercialization with several clinical evidence studies in the planning phase and also ongoing. IMMray™ PanCan-d is the only blood-based test available for early detection of pancreatic cancer in stage I and stage II when the cancer is still resectable. Diagnosing patients in stage I and stage II could increase the overall 5-year survival rate from 3-4% to approx. 59%1.
Immunovia’s solution combines a single-chain fragment variable (scFv) antibody library in an array-based set-up, antibody biomarker signatures and an advanced, in-house developed clinical algorithm and software for interpreting the data. The company has its own antibody library, antibody production and purification as well as its own chip/array production. Our clinical laboratory services are now undergoing validation for ISO accreditation.
The company’s mission is to establish its blood-based test for early diagnosis of pancreatic cancer as a standard amongst pancreatologists and diabetes physicians worldwide for detecting pancreatic cancer in high-risk groups much earlier than is possible today.
Ultimately, Immunovia’s vision is to significantly improve the survival rates, choice of treatment and life quality of cancer patients and their families.
- Shimizu Y. et al., Small carcinoma of the pancreas is curable, Journal of Gastroenterology and Hepatology 2005;20:1591-1594.